Reversal of inflammatory reprogramming by vasodilator agents in pulmonary hypertension [PDF]
ERJ Open ResearchBackground Pulmonary arterial hypertension (PAH) is a deadly disease without effective non-invasive diagnostic and prognostic testing. It remains unclear whether vasodilators reverse inflammatory activation, a part of PAH pathogenesis.
Anna Kirillova +12 more
doaj +2 more sources
Age and Vasodilator Response to Different Hyperemic Agents: Adenosine versus Contrast Medium [PDF]
Reviews in Cardiovascular MedicineBackground: Age-related remodelling has the potential to affect the microvascular response to hyperemic stimuli. However, its precise effects on the vasodilatory response to adenosine and contrast medium, as well as its influence on fractional flow ...
Domenico Galante +18 more
doaj +2 more sources
Direct Vasodilators and Sympatholytic Agents [PDF]
Journal of Cardiovascular Pharmacology and Therapeutics, 2015 Direct vasodilators and sympatholytic agents were some of the first antihypertensive medications discovered and utilized in the past century. However, side effect profiles and the advent of newer antihypertensive drug classes have reduced the use of these agents in recent decades.
Meghan N, McComb +2 more
openaire +3 more sources
Levosimendan, a New Inotropic and Vasodilator Agent [PDF]
Anesthesiology, 2006 Several clinical studies suggest substantial limitations of currently available positive inotropic substances, including beta1-adrenoceptor agonists and phosphodiesterase III inhibitors in the short- and long-term treatment of heart failure. The reasons for these detrimental effects are related to the mechanism of action of these drugs, including ...
Wolfgang G. Toller +2 more
openaire +3 more sources
Vasodilator agents improve hemodialysis vascular access patency: A population-based study from Korea. [PDF]
Medicine (Baltimore), 2021 Kim DH +9 more
europepmc +2 more sources
Loss of response to calcium channel blockers after long-term follow-up treatment in patients with idiopathic pulmonary arterial hypertension [PDF]
Jornal Brasileiro de Pneumologia, 2023 Idiopathic pulmonary arterial hypertension (PAH) patients with a positive response to acute vasodilator challenge and a clinical response to calcium channel blockers (CCBs) for at least one year are traditionally designated true responders. Nevertheless,
Bruna Piloto +5 more
doaj +1 more source
Critical care management of pulmonary arterial hypertension in pregnancy: the pre-, peri- and post-partum stages [PDF]
Acute and Critical Care, 2021 The mortality rate of pulmonary hypertension in pregnancy is 25%–56%. Pulmonary arterial hypertension is the highest incidence among this group, especially in young women.
Vorakamol Phoophiboon +4 more
doaj +1 more source
Effect of Papaverine on Left Internal Mammary Artery Flow: Topical Spraying versus Perivascular Injection Method [PDF]
Brazilian Journal of Cardiovascular Surgery, 2020 Objective: To analyze two techniques of papaverine application, topical spray on the harvested left internal mammary artery (LIMA) and perivascular injection, to find out their ability to improve LIMA flow.
Girish Gowda S L +4 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Postischemic cerebral hypoperfusion has been indicated as an important contributing factor to secondary cerebral injury after cardiac arrest. We evaluated the effects of sodium nitroprusside administered via a subdural intracranial catheter on
Hyoung Youn Lee +8 more
doaj +1 more source
Prognostic Impact of Chronic Vasodilator Therapy in Patients With Vasospastic Angina
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Chronic vasodilator therapy with long‐acting nitrate is frequently used to treat vasospastic angina. However, the clinical benefits of this approach are controversial.
Yongwhan Lim +18 more
doaj +1 more source